RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A methodological comparison of two European primary care databases and replication in a US claims database
inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction
Afonso, A., Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana Hortoneda, E., Souverein, P., Wang, Y., Korevaar, JC., Hasford, J., Reynolds, R., de, G., Schlienger, R., Klungel, O., & Rottenkolber, M. (2016). A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. European Journal of Clinical Pharmacology, 72(9), 1105-1116. https://doi.org/10.1007/s00228-016-2071-8
For asthma or COPD patients, no statistically significant AMI-aHRs (age- and sex-adjusted) were found in the primary analysis. For patients with both diagnoses, a decreased AMI-aHR was found for current vs. recent LABA use in the CPRD GOLD (0.78; 95 % CI 0.68-0.90) and in Mondriaan (0.55; 95 % CI 0.28-1.08), too. The replication study yielded similar results. Adjusting for concomitant medication use and comorbidities, in addition to age and sex, had little impact on the results. By using a common protocol, we observed similar results in the primary analysis performed in two GP databases and in the replication study in a claims database. Regarding differences between databases, a common protocol facilitates interpreting results due to minimized methodological variations. However, results of multinational comparative observational studies might be affected by bias not fully addressed by a common protocol.